<div id="readability-page-1">08:29 AM EST, 11/26/2025 (MT Newswires) -- BioNTech (BNTX) said Wednesday that CureVac ( CVAC ) shareholders approved matters related to BioNTech's exchange offer at an extraordinary general meeting, with 99.16% voting in favor of the proposals.The exchange ratio has been set at 0.05363 of a BioNTech American depository share for each CureVac ( CVAC ) share, based on the 10-day volume-weighted average price of BioNTech ADSs through Nov. 25, 2025, the company said.BioNTech said it expects to complete the offer as soon as practicable. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

BNTX

BioNTech 宣布，CureVac 股东以 99.16% 的投票支持批准了交换提议。交换比例设定为每股 CureVac 股票兑换 0.05363 股 BioNTech 美国存托股票（ADS）。BioNTech 预计将很快完成该提议

BioNTech 对 CureVac 的公开交换要约已获得股东的批准